SPP1 and myeloid sarcoma: Notable differences emerged in MS patients following the administration of NTZ (Figure 9C), specifically after a minimum of 6 months of treatment, and our findings suggest that OPN could serve as a biomarker for evaluating the effectiveness of treatment, as expected provided the direct functional link of OPN with this MS therapy.